353 results about "Intravenous therapy" patented technology

The invention discloses an RGD-click chemical crosslinking siRNA nano-carrier, a preparation method thereof and application of the nano-carrier in preparation of a medicine for treating secondary thyroidism, and belongs to the technical field of medicines.The nano-carrier is RGD-PEG-PLys (N), and the preparation method of the nano-carrier comprises the steps of synthesis of PLys (ss-DBCO), synthesis of RGD-PEG-PLys (N) and the like. According to the application, the nano-carrier is used for preparing siRNA composite nanoparticles; vascular endothelial targeting (RGD), dynamic stability (click crosslinking) and microenvironment responsiveness (disulfide bond) are organically combined for the first time to achieve mutual synergistic interaction, and the effect ceiling of an existing material is broken through; according to the siRNA composite nanoparticle, the silence effect of the PTH gene as long as 70 days can be achieved through single intravenous injection, the PTH inhibition rate is larger than 85%, the siRNA accumulation amount in parathyroid gland tissue is remarkably increased through RGD targeting (8.6 times that of a non-targeting group), the liver and kidney distribution amount is reduced by 60%, and the system toxicity is controllable.

The invention belongs to the technical field of drug delivery, and particularly relates to an M-coated PLGA-10BX compound as well as a preparation method and application thereof. The preparation method comprises the following steps: preparing 10B-enriched boron nitride (h-10BN); extracting a cell membrane of the macrophage RAW264.7; polylactic acid-glycolic acid copolymer (PLGA) nano particles loaded with h-10BN are prepared; and finally, the bionic nano platform M (at) PLGA-10BN based on the macrophage membrane is prepared. The bionic nano-platform prepared by the invention is uniform in particle size and morphology, has relatively high biological safety, and has no obvious damage to various tissues and visceral organs. The compound can be used as a general platform for boron compound delivery, can also be used as an immune activator, is suitable for intravenous injection administration, and expands the application of boron neutron capture therapy (BNCT) in treatment of glioblastoma (GBM).

The invention discloses a method for constructing an atrial fibrillation small animal model through succinic acid induction and application, and the method comprises the following steps: in an animal model construction period, enabling a small animal to ingest an aqueous solution containing succinic acid or all pharmaceutically acceptable salts of succinic acid every day, and finishing the modeling period to obtain the animal model. Compared with a traditional angiotensin AngII administration method, the atrial fibrillation small animal model has the advantages that the cost of a medicine for constructing the animal model is lower, the economic benefit is higher, and the atrial fibrillation induction effect is better; the model represents the most common atrial fibrillation type in clinic, and compared with an acute transient atrial fibrillation model, the research and application range is wider; compared with tail vein injection, intraperitoneal injection, subcutaneous pump burying and other modes, the non-creative model has the advantages that damage to small animals is smaller, and the requirement for the operation technology is low.

The invention relates to the technical field of medicines, in particular to application of lycium barbarum-derived extracellular vesicles in preparation of a medicine for treating acute kidney injury. The used extracellular vesicles derived from Chinese wolfberry fruits have a lipid bilayer membrane structure, are good in stability, free of remarkable toxicity, good in blood compatibility and high in-vivo safety after long-term intravenous injection, are used for preparing the medicine for treating the acute kidney injury, and can reduce apoptosis, inhibit rising of blood urea nitrogen and creatinine levels and relieve injury of kidney tissues; the invention further provides application of the extracellular vesicles derived from the Chinese wolfberry fruits in preparation of the medicine for treating the lung injury disease, the weight loss is relieved, lung tissue is protected, meanwhile, the pulmonary alveolar-capillary barrier can be repaired, and in addition, the medicine can be used for treating the lung injury disease. The invention also provides application of the extracellular vesicles derived from Chinese wolfberry fruits in preparation of nuclear transcription factor kappa B inhibitors and / or inhibition of apoptosis and / or repair of pulmonary alveolar capillary barriers.

The invention provides a POCD treatment medicine composition with dendrobine delivered by a nano-carrier and application, and belongs to the technical field of medicine. The composition consists of dendrobine, a nano-carrier material and a stabilizer, wherein a nano-carrier is PLGA (poly (lactic-co-glycolic acid)) nanoparticles or lipidosome. The particle size of the composition is 50-150nm, the polydispersity index is less than 0.3, and the loading capacity of dendrobine is 5-15%. The invention also provides two preparation methods of the composition. The PLGA nanoparticles are prepared by adopting an emulsification-solvent evaporation method; the liposome is prepared by adopting a film hydration-ultrasonic extrusion method, and each process parameter is specifically limited. The pharmaceutical composition can significantly improve the brain targeting and bioavailability of dendrobine, and can be used for preparing drugs for preventing or treating postoperative cognitive impairment (POCD), and the administration route can be intravenous injection or nasal administration.

The invention relates to the technical field of exosome preparations, and particularly discloses an exosome nasal delivery preparation as well as a preparation method and application thereof. The preparation comprises the following components: 1 * 10 < 9 >-5 * 10 < 11 > particle number / ml of exosome, 1%-4% w / v of a saccharide protective agent, 0.5%-4.5% w / v of an alcohol protective agent, 0.05%-1% w / v of an absorption enhancer and a solvent. The exosome nasal delivery preparation can break through the blood brain barrier and quickly take effect, and the intracerebral delivery efficiency of the exosome nasal delivery preparation can be improved by 2-5 times compared with intravenous injection. The nasal administration preparation can be used for treating central nervous system diseases such as cerebral apoplexy and the like, and can remarkably improve the neurological function, reduce the cerebral infarction area and promote functional recovery.

An anesthetic equipment storage and waste air management module configured to housing electronic and electromechanical surgical equipment including a system to measure and record administration of one or more IV medications or fluids for IV administration. The module can include a housing having a lower section and a tower-like upper section, wherein the lower section is configured to house unrelated waste heat-producing electronic and electromechanical surgical equipment. The module can also include a cowling that substantially confines waste heat generated by the unrelated waste heat-producing electronic and electromechanical surgical equipment, and can include a system for measuring and recording the administration of the one or more IV medications and fluids.

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The present invention provides methods of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof comprising intravenously administering sotalol hydrochloride to a subject in need thereof. Embodiments of the present invention further provide novel methods of intravenously administering sotalol hydrochloride for example in pediatric patients. The present invention provides a novel intravenous, prophylactic, antiarrhythmic method of sotalol administration.

The invention relates to medicine, in particular to gerontology and therapy and can be used for treating sarcopenia in elderly patients.Summary of the invention consists in alternating for 1…2 days the intravenous administration of ozonized 0.9% NaCl solution and major autohemotherapy, namely 500 mL of a 0.9% NaCl solution ozonized with an ozone-oxygen mixture, with an ozone concentration of 5…10 µg / mL, are administered, and major autohemotherapy consists in collecting 300…400 mL of venous blood from the patient, which is ozonized, with an ozone concentration of 15 µg / mL and transfused to the patient, the treatment course includes 8…10 consecutive procedures, then it is extended with minor autohemotherapy, which consists in collecting 5…10 mL of venous blood, which is ozonized, with an ozone concentration of 15 µg / mL and administered intramuscularly every 10th day of alternation and includes 3 consecutive procedures, and the ozonized 0.9% NaCl solution is administered for up to 6…8 weeks.

The invention relates to a non-gadolinium magnetic resonance contrast agent and a preparation method thereof, and belongs to the field of contrast agents. The invention aims to provide a non-gadolinium contrast agent with high biological safety aiming at the risks of renal fibrosis and cerebral deposition existing in a gadolinium-based magnetic resonance contrast agent. The invention provides a phosphate group modified non-gadolinium magnetic resonance contrast agent. The phosphate group modified non-gadolinium magnetic resonance contrast agent consists of a ligand of a phosphate group substituted trans-cyclohexanediamine tetraacetic acid derivative (tmPCDTA or tqPCDTA) and metal ions Fe < 3 + > or Mn < 2 + >, the contrast agent disclosed by the invention is high in biological safety: endogenous Fe < 3 + > / Mn < 2 + > is used for replacing gadolinium, and cell experiments prove that the survival rate of 4T1 cells is not influenced at the concentration of 500 mu M; clinical applicability is high, kidney excretion is rapid, bladder signals are enhanced 3-5 minutes after mouse intravenous injection, and liver retention is avoided.

The application discloses a kind of hardness correlation liver cancer lung premetastatic niche mouse model construction method, it includes the following steps: (1) in vitro enrichment respectively on the low hardness substrate of hardness 6kPa and the high hardness substrate of hardness 16kPa, the condition culture supernatant of mouse liver cancer cell Hepa1-6 that is cultured and grows, respectively named mL-CM and mH-CM;(2) mL-CM and mH-CM are respectively injected into two groups of mice using tail vein injection mode, every 1 day injection 1 time, until the 26th day, during continuous monitoring the recruitment of BMDCs in fresh lung tissue, while with the induction endpoint, i.e. 26th day premetastatic niche mark feature detection includes lung tissue matrix remodeling, immunosuppression, angiogenesis, vascular permeability and inflammation etc..The method has the advantages of short modeling cycle, easy operation, controllable induction condition, can comprehensively and accurately evaluate the common characteristics of liver cancer lung premetastatic niche formation etc..

The invention relates to an ultrasonic response bionic piezoelectric nano-drug for treating epilepsy as well as a preparation method and application of the ultrasonic response bionic piezoelectric nano-drug. The ultrasonic response bionic piezoelectric nano-drug comprises hafnium-based piezoelectric nano-particles UIO-66-NH2 etched by sulfuric acid, an anti-epileptic drug, a microglial cell membrane and transferrin receptor targeting peptide, wherein the anti-epileptic drug is loaded in hafnium-based piezoelectric nanoparticles etched by sulfuric acid to form a drug loading core; the microcolloid cell membrane coats the outer surface of the drug loading core; the transferrin receptor targeting peptide is connected to a microglial cell membrane. The ultrasonic response bionic piezoelectric nano-drug is high in brain entering efficiency, stable in drug release amount and clear in preparation method path, is suitable for targeted delivery of various anti-epileptic drugs and treatment and research of nervous system diseases such as epilepsy, can adopt an intravenous injection administration mode and non-invasive administration, can avoid injury caused by an operation, and has a good application prospect. The electrical stimulation is generated in vivo without implanting and taking out the electrode, so that secondary injury and infection are avoided.

A venous monitoring system is disclosed that can include a fluid passageway formed in a housing to receive and direct fluid through the housing, a sensor coupled to the fluid passageway to detect data of the fluid in the fluid passageway, a communication unit to communicate data sensed by the sensor, and a power source, wherein the system of the present disclosure can be used for venous monitoring when coupled to a catheter or an intravenous set, or can include a catheter needle extending from the housing, and wherein the system of the present disclosure can detect characteristics such as placement of a catheter, fluid passageway occlusion or patency, and catheter extravasation or infiltration.

The utility model discloses an intravenous injection tool for nursing teaching, and particularly relates to the technical field of teaching tools, the intravenous injection tool comprises a simulation arm, and a plurality of simulation blood vessels are arranged in the simulation arm according to a real human body structure; each simulated blood vessel comprises a supporting tube on the inner layer and a flexible sensor wrapping the outer layer of the supporting tube; the signal output end of the flexible sensor is connected to the input end of a signal conditioning circuit; the output end of the signal conditioning circuit is connected to the input end of the comparator; the output end of the comparator is connected to the control end of the alarm and the control end of the illuminating lamp. And finally, the power supply ends of the flexible sensor, the alarm and the illuminating lamp are connected to the corresponding output ends of the power supply through wires. The bottom end of the simulation arm is provided with an adjusting structure and a protruding structure.

This invention discloses a phosphorylated diamine morpholino oligonucleotide drug that regulates PAPOLA expression and its application, belonging to the field of biomedical technology. The nucleotide sequence of the drug is shown in SEQ ID NO:1, targeting the coding region of human PAPOLA mRNA. The formulation is a lyophilized powder for injection, with excipients including mannitol and phosphate buffer. This invention also discloses the application of this drug in the preparation of a treatment for gastric cancer, specifically advanced gastric cancer with high PAPOLA expression. The drug is administered intravenously at a dose of 8-12 mg / kg every 3 days. Its mechanism of action is to block PAPOLA protein translation, inhibit the G1 / S phase transition of gastric cancer cells, and induce apoptosis. In vitro and in vivo experiments have confirmed that this drug can specifically inhibit the proliferation and growth of gastric cancer cells, providing a new treatment option for advanced gastric cancer.

A flow control device includes an upper housing, a lower housing, a chamber interposed between and defined by the upper housing and the lower housing, and a valve member. The upper housing includes a primary inlet and a secondary inlet, the primary inlet having an inner surface defining a cavity. The lower housing defines an outlet of the flow control device. The chamber fluidly connects the primary inlet and the secondary inlet with the outlet. The valve member is at least partially reciprocatingly disposed in the cavity and partially reciprocatingly disposed in the chamber to (i) selectively permit fluid to flow into the main inlet in a first direction when the fluid level in the chamber is below a predetermined level, and (ii) selectively permit fluid to flow into the main inlet in a second direction when the fluid level in the chamber is above the predetermined level. The fluid is prevented from flowing back in a second direction opposite to the first direction.

The invention involves a novel method of converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL by administering at least a loading dose of dofetilide intravenously, or if that fails cardioversion and a maintenance infusion followed by a switch to chronic oral dosing.

The present disclosure relates to a method of treatment or prophylaxis of a preterm infant by administering intravenously a therapeutic amount of a composition comprising IGF-1 and IBGBP-3 in combination with a therapy selected from the group comprising: caffeine, fentanyl, fluconazole, gentamicin, insulin, midazolam, morphine, low dose norepinephrine, vancomycin concentrations of 5 mg / ml or less, parenteral nutrition (or a composition for the same use) and combinations thereof.

The invention provides an injection for inducing mesenchymal stem cells. The induced mesenchymal stem cell injection is prepared from induced mesenchymal stem cells modified by hepatocyte growth factors with the cell density being 1.0 * 10 < 5 >-2.0 * 10 < 7 > / ml, HSA with the mass concentration being 0.25%-6%, DMSO with the mass concentration being 5%-10%, glucose with the mass concentration being larger than 0 and smaller than 1%, compound amino acid with the concentration being 0.5-5 mg / mL and the balance compound electrolyte injection. And the induced mesenchymal stem cell injection has a pH value of 6.8 to 7.5. The induced mesenchymal stem cell injection is good in homogeneity, small in batch difference and stable in curative effect, can effectively promote damaged tissue repair, can be directly intravenously injected after cryopreservation and recovery, keeps high cell viability and drug activity, achieves an excellent treatment effect, has good room-temperature stability, is convenient to transport and store, and is suitable for clinical application. The method is suitable for different clinical application occasions, and the clinical application range of the mesenchymal stem cells is expanded.

Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

The invention belongs to the technical field of medicine synthesis, and particularly relates to a cytidine precursor compound as well as a preparation method and application thereof. The cytidine precursor compound provided by the invention is a compound with a structure as shown in a formula (I) or a pharmaceutically acceptable salt thereof, in the formula (I), R2 is selected from one of hydrogen, formyl, acetyl, propionyl, n-butyryl and isobutyryl; r1, R3, R4, R5 and R6 are respectively and independently selected from two or three of hydrogen, hydroxyl and fluorine. The cytidine precursor compound provided by the invention is convenient to prepare oral and intravenous injection preparations, can be effectively converted into a raw drug in vivo, has bioavailability and tumor aggregation which are obviously higher than those of a cytidine raw drug, has an excellent drug treatment effect, has obvious clinical advantages, and greatly meets the clinical application requirements of cytidine antitumor drugs.

The utility model provides an arm nursing practice device which comprises a simulation blood vessel assembly and a puncture assembly, the simulation blood vessel assembly comprises a first air pump, a second air pump, a simulation blood vessel, a display and a controller; the simulated blood vessel comprises an inner layer and an outer layer, the inner layer and the outer layer are connected with each other, and a cavity is formed between the inner layer and the outer layer; the first air pump is communicated with the cavity, the second air pump is connected with the inner layer, and the first air pump, the second air pump and the display are connected with the controller; the puncture assembly comprises an injection needle body, an air pressure detector and a control panel, the air pressure detector is installed in the injection needle body and connected with the control panel, and the control panel is connected with the controller. The intravenous injection puncture training device is mainly used for achieving puncture training of intravenous injection, and can solve the technical problems that in the prior art, after puncture is conducted, leakage of simulation blood is likely to be caused, pollution is caused, simulation blood needs to be added in the training process, and it is inconvenient for multiple persons to conduct training for a long time.

The invention discloses a cationic peptide compound for targeting cartilage as well as a preparation method and application of the cationic peptide compound. The cationic peptide compound has a structural general formula as shown in the specification: R-(Xa-Nlys-Yb) n, wherein R is H, a drug active molecule or a group containing a signal marker, and X and Y are independently selected from any one of glycine residues and imidic acid residues; nlys is a residue of N-(4-aminobutyl) glycine; a and b are independently selected from any integer between 0 and 3; n is any positive integer from 3 to 10. The compound can target a glycosaminoglycan chain in cartilage through electrostatic interaction, has an effect of resisting protease degradation, and is beneficial to prolonging the in-vivo circulation time. The compound supports systemic administration, can be used for marking whole body cartilage through intravenous injection, is used for monitoring cartilage development, aging and pathological changes in real time, and has wide application potential in the aspects of molecular imaging, drug delivery and biological materials for treating cartilage-related diseases.

The present application relates to a kind of FAPi, FAPi intermediate, FAPi modified HSP47siRNA loaded lipid nanoparticles and its application, belong to the field of biological medicine.The inventor constructs a kind of HSP47siRNA loaded lipid nanoparticles (FAPi-LNP / siHSP47) of Fibroblast activation protein inhibitor (FAPi) modification in view of the problems of high morbidity of existing technology liver fibrosis, so far no medicine, and ordinary LNP mainly target delivery to liver parenchymal cell after intravenous injection, and cannot enter the activated hepatic stellate cell (HSC) that plays a key role in the development of liver fibrosis.The expression of HSP47 can be effectively knocked down by the mediation of the high expression of Fibroblast activation protein on the surface of activated HSC, and the content of liver fibrosis marker protein a-SMA can be reduced.Compared with LNP without FAPi modification, FAPi-LNP / siHSP47 actively targets activated HSC after entering liver tissue, enters cell under the mediation of FAP, significantly knocks down the expression of HSP47, reduces collagen deposition, and significantly improves liver fibrosis.

The present disclosure provides a method of administering a low dose soluble protein to a subject in need thereof, wherein the method comprises (a) adding an intravenous solution stabilizer ("IVSS") to an isotonic aqueous solution in a container to form a pretreated container, (b) adding an amount from a protein stock solution to the pretreated container of step (a) to form a low dose protein solution, and (c) administering the low dose protein solution of step (b) to the subject. Optionally, the dose of the soluble protein to be administered to the subject is an ultra-low dose protein, wherein the low dose protein solution undergoes a further dilution step. In particular, the method of administering an ultra-low dose soluble protein comprises: (a) adding an IVSS to an isotonic aqueous solution in a first container to form a first pretreated container, (b) adding an amount from the protein stock solution to the first pretreated container to form a low dose protein solution; (c) adding an IVSS to an isotonic aqueous solution in a second container to form a second pretreated container; and (d) adding an amount of the low dose protein solution in step (b) to the second pretreated container of step (c) to form an ultra-low dose protein solution, and (e) administering the low dose protein solution of step (b) to an individual in need thereof.

The invention discloses an amniotic epithelial cell-derived exosome for treating gestational hypertension and application thereof, and belongs to the technical field of biological medicines. The exosome (hAECs-exos) is obtained by secreting and extracting human amniotic epithelial cells (hAECs), the particle size distribution of the exosome (hAECs-exos) is 30-150 nm, and the exosome (hAECs-exos) expresses exosome specific markers CD9, CD63 and CD81. The invention also provides a preparation method of the exosome. The preparation method comprises the following steps: isolated culture of hAECs, and ultracentrifugal extraction and identification of the exosome. Animal experiments prove that when the exosome is applied to a gestational hypertension disease model animal in an intravenous injection mode, the blood pressure and urine protein level of the gestational hypertension disease model animal can be remarkably reduced, and the fetal rat dysplasia condition is improved. The invention provides a brand-new and effective biological preparation candidate scheme for the treatment of the gestational hypertension disease.

This invention discloses a tactile-visual collaborative realistic simulation method for intravenous puncture in virtual training for intravenous therapy nurses, belonging to the field of medical virtual simulation training technology. Addressing the problems of single tactile feedback and poor coordination between tactile and visual feedback in existing systems, this invention uses layered collision modeling to detect the needle tip's level in real time and trigger events; it generates multi-level tactile and visual blood return feedback signals based on the needle tip level and outputs them synchronously based on the same event. This invention allows trainees to simultaneously experience the dual sensations of "feeling emptiness" and "stable blood return within the needle tube" during puncture, achieving close coordination between tactile and visual feedback and helping trainees establish correct neuromuscular memory. This invention can be widely applied in the field of virtual simulation training for nursing skills, significantly improving the realism of training and operational recognition.

This invention discloses a biomimetic nanocomposite, its preparation method, and its application in the preparation of products for treating atherosclerosis, belonging to the field of pharmaceutical preparation technology. The biomimetic nanocomposite is an Ir-TiO2 metal nanozyme encapsulated in an M2 macrophage membrane. This invention prepares a structurally biomimetic nanocomposite by coating Ir-TiO2 nanoparticles with an M2 macrophage membrane. After intravenous injection, the formed biomimetic nanocomposite actively targets endothelial cells in atherosclerotic lesions, releasing Ir-TiO2 antagonistically into the cytoplasm of plaque-containing endothelial cells and inflammatory macrophages. Once Ir-TiO2 reaches the lesion site, it exerts an enzymatic effect to achieve anti-inflammatory activity and promotes cholesterol excretion from inflammatory cells such as macrophages and smooth muscle cells at the lesion site, reducing intracellular lipid deposition, reducing foam cell formation, and promoting plaque growth. This nanotherapy can effectively prevent the progression of inflammation in atherosclerotic lesions and alleviate atherosclerosis.

[Problem] To provide a method for treatment of adenovirus infection or disease associated with adenovirus infection. [Solution] Provided is a pharmaceutical composition for use in the treatment of adenovirus infection or disease associated with adenovirus infection, comprising brincidofovir, a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein the treatment comprises (i) intravenously administering, to a human subject, the brincidofovir, pharmaceutically acceptable salt thereof, or solvate thereof at 0.38 to 0.42 mg / kg twice weekly, or (ii) intravenously administering, to a human subject, the brincidofovir, pharmaceutically acceptable salt thereof, or solvate thereof at 18 to 22 mg / dose twice weekly.